Medtronic.jpg” alt=”medtronic” width=”300″ height=”168″ />

Medtronic has reported that the first patients have been randomised in Symplicity HTN-4, the first randomised clinical trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in US patients.

The study will assess the Symplicity renal denervation system in patients with moderate uncontrolled hypertension, with systolic blood pressure greater than or equal to 140mm Hg and less than 160mm Hg, despite treatment with three or more anti-hypertensive medications of different classes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Symplicity HTN-4 randomised its first patients at Medical University of South Carolina (MUSC), Piedmont Heart Institute and Duke University Medical Center. It is Medtronic’s second randomised, controlled renal denervation clinical trial in the US.

Symplicity HTN-4 builds upon the Symplicity HTN-3 study, Medtronic’s pivotal US clinical trial of the Symplicity renal denervation system.

Medtronic Renal Denervation vice president and general manager Nina Goodheart said: “Symplicity HTN-4 demonstrates Medtronic’s commitment to providing randomised safety and efficacy data for renal denervation in a wide variety of patients, as well as helping increase our understanding of the potential benefit of renal denervation for more patients with treatment resistant hypertension.”

“Symplicity HTN-4 is helping increase our understanding of the potential benefit of renal denervation for more patients with treatment resistant hypertension.”

Symplicity HTN-4 will enrol up to 580 patients at approximately 100 sites, continuing to target a patient population in line with the uncontrolled hypertension defined by the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7), the American Heart Association and the European Society of Hypertension.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Similar to the US pivotal trial, Symplicity HTN-3 study evaluated patients with uncontrolled hypertension with a systolic blood pressure greater than or equal to 160mm Hg. The Symplicity HTN-4 study will be blinded and include a sham control.

The principal investigators of Symplicity HTN-4 are Dr David Kandzari, director and chief scientific officer of Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, and Dr Michael Weber, professor of medicine, Division of Cardiovascular Medicine, at the SUNY Downstate College of Medicine in Brooklyn, New York.

The Symplicity renal denervation system consists of a proprietary generator and flexible catheter, which delivers a controlled, low-power radio-frequency (RF) energy through a proprietary algorithm, or pattern, aiming to deactivate the surrounding renal nerves.

While the Symplicity system had received CE mark approval in 2008 it is currently available for only investigational use in the US.

Image: The Symplicity renal denervation system. Photo: courtesy of Medtronic Inc.